News - Page 69 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Bullseye Chart: The Psychedelic Drug Development Pipeline

Bullseye Chart: The Psychedelic Drug Development Pipeline

Post published:February 8, 2023
Post category:2022 Year in Review

Read more about the article Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Post published:February 8, 2023
Post category:Press Release

Read more about the article Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First Step, Potential International Catalyst

Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First Step, Potential International Catalyst

Post published:February 8, 2023
Post category:Opinions

Read more about the article Panel: Neuroimaging in Psychedelic Research

Panel: Neuroimaging in Psychedelic Research

Post published:February 7, 2023
Post category:2022 Year in Review

Read more about the article Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Post published:February 7, 2023
Post category:Press Release

Read more about the article PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

Post published:February 7, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Post published:February 6, 2023
Post category:Press Release

Read more about the article Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Post published:February 6, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Post published:February 3, 2023
Post category:Psychedelic Bulletin

Read more about the article Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Post published:February 3, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.